Brown, J. E. and Coleman, R. E. orcid.org/0000-0002-4275-1043 (2001) The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Research, 4 (1). pp. 24-29. ISSN 1465-5411
Abstract
At least 25% of patients with breast cancer develop skeletal metastases, with bone the site of disease producing the greatest morbidity. It is apparent that the bisphosphonates present an important component of the treatment strategy. They are now the treatment of choice in tumour-induced hypercalcaemia, and they can reduce bone pain and skeletal complications such as pathological fractures. In addition, bisphosphonates are being increasingly evaluated in the prevention of bone metastases and to prevent and treat cancer therapy-induced osteoporosis. Ongoing research is aimed at trying to define the optimum route, dose, schedule and type of bisphosphonate.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2002 BioMed Central Ltd. Open Access |
Keywords: | bisphosphonates; breast cancer; cancer-induced bone disease; METASTATIC BONE-DISEASE; DOUBLE-BLIND; CONTROLLED TRIAL; SKELETAL COMPLICATIONS; PAMIDRONATE; CLODRONATE; MORBIDITY; EFFICACY; WOMEN |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > The Medical School (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology and Metabolism (Sheffield) The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 21 Nov 2016 10:26 |
Last Modified: | 21 Nov 2016 10:26 |
Published Version: | http://dx.doi.org/10.1186/bcr413 |
Status: | Published |
Publisher: | BioMed Central |
Refereed: | Yes |
Identification Number: | 10.1186/bcr413 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:107777 |